Here I present to you exclusively an undervalued share that few analysts have on their radar. The Cel-Sci share has recovered significantly from its lows reached in 2023 and formed a wave 1. There has been a correction, so we can expect big upward waves 3 and 5 soon. From an option sentiment perspective, the stock is overly bearish. However, an overly negative put-call ratio is a contra-indicator, so we are bullish on the stock. We expect Cel-Sci's share price to double in the coming months. About the company:
Cel-Sci Corporation, also known as CVM, is indeed an American biotechnology company specializing in the research and development of immunotherapy products for treating cancer, autoimmune diseases, and infectious diseases. The company is actively testing drugs in these areas of application.
Founded in Germany in 1983, Cel-Sci went public in the same year. Its shares are currently traded on the NYSE American and the Frankfurt Stock Exchange, among others.
Cel-Sci Corporation, also known as CVM, is indeed an American biotechnology company specializing in the research and development of immunotherapy products for treating cancer, autoimmune diseases, and infectious diseases. The company is actively testing drugs in these areas of application.
Founded in Germany in 1983, Cel-Sci went public in the same year. Its shares are currently traded on the NYSE American and the Frankfurt Stock Exchange, among others.